The funds will support the development of LoQus23’s lead candidate, its MutSβ inhibitor, as it enters clinical development.

BPGbio to present novel Huntington's Disease and Alzheimer's Disease research at the Society for Neuroscience 2024 annual meeting.

The proceeds of the financing will support the development of LoQus23’s lead candidate, a small molecule inhibitor that is ...

The Food and Drug Administration has granted Fast Track designation to PTC518 for the treatment of Huntington disease (HD).

Researchers have discovered that the protein mutated in patients with Huntington’s disease doesn’t repair DNA as intended, ...

Cambridge biotech LoQus23 Therapeutics has closed a £35 million (c.$43m) Series A to advance its fight against Huntington’s ...

The Team Hope 5K Walk is being hosted by the Huntington’s Disease Society of America. The event will be on October 6 at ...

A teacher from Chesapeake is determined to run in the NYC marathon following a life changing medical diagnosis.

A new study has uncovered a startling revelation: rare genetic disorders caused by repetitive DNA sequences may be up to ...

Researchers at Queen Mary University of London have conducted the most comprehensive genetic sequencing study to date, ...

Neurocrine Biosciences' stock dropped after a lackluster trial. Click here to read more about the potential for this biotech ...